TW202011982A - 肽調配物及其用途 - Google Patents

肽調配物及其用途 Download PDF

Info

Publication number: TW202011982A
Authority: TW; Taiwan
Prior art keywords: pharmaceutical composition; peptides; composition according; peptide; amino acids
Prior art date: 2018-04-19

Application number

TW108113861A

Other languages

English (en)

Chinese (zh)

Inventor

正欣董

羅賓潔西卡艾瑟特

Original Assignee

美商尼恩醫療公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-04-19

Filing date

2019-04-19

Publication date

2020-04-01

2019-04-19 Application filed by 美商尼恩醫療公司 filed Critical 美商尼恩醫療公司

2020-04-01 Publication of TW202011982A publication Critical patent/TW202011982A/zh

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 546
239000000203 mixture Substances 0.000 title claims abstract description 193
238000009472 formulation Methods 0.000 title description 44
239000003002 pH adjusting agent Substances 0.000 claims abstract description 109
238000000034 method Methods 0.000 claims abstract description 82
239000003937 drug carrier Substances 0.000 claims abstract description 42
239000002671 adjuvant Substances 0.000 claims abstract description 27
239000002955 immunomodulating agent Substances 0.000 claims abstract description 21
229940121354 immunomodulator Drugs 0.000 claims abstract description 18
230000002584 immunomodulator Effects 0.000 claims abstract description 16
102000004196 processed proteins & peptides Human genes 0.000 claims description 251
239000008194 pharmaceutical composition Substances 0.000 claims description 222
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 124
150000001413 amino acids Chemical class 0.000 claims description 114
206010028980 Neoplasm Diseases 0.000 claims description 113
239000000243 solution Substances 0.000 claims description 74
239000000427 antigen Substances 0.000 claims description 67
108091007433 antigens Proteins 0.000 claims description 64
102000036639 antigens Human genes 0.000 claims description 64
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 61
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 54
229960005486 vaccine Drugs 0.000 claims description 46
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
239000002253 acid Substances 0.000 claims description 36
150000003839 salts Chemical class 0.000 claims description 35
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
201000010099 disease Diseases 0.000 claims description 24
230000001965 increasing effect Effects 0.000 claims description 23
235000000346 sugar Nutrition 0.000 claims description 22
-1 amino acids Amino acids Chemical class 0.000 claims description 20
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
239000001384 succinic acid Substances 0.000 claims description 18
201000011510 cancer Diseases 0.000 claims description 17
239000008121 dextrose Substances 0.000 claims description 17
239000003814 drug Substances 0.000 claims description 16
230000003053 immunization Effects 0.000 claims description 16
238000002649 immunization Methods 0.000 claims description 16
238000001914 filtration Methods 0.000 claims description 15
230000002163 immunogen Effects 0.000 claims description 15
239000003795 chemical substances by application Substances 0.000 claims description 14
239000007788 liquid Substances 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 14
208000035269 cancer or benign tumor Diseases 0.000 claims description 13
239000007864 aqueous solution Substances 0.000 claims description 12
238000002255 vaccination Methods 0.000 claims description 12
230000001613 neoplastic effect Effects 0.000 claims description 11
239000002245 particle Substances 0.000 claims description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
241000700605 Viruses Species 0.000 claims description 7
BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 5
229950010550 resiquimod Drugs 0.000 claims description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
229960002751 imiquimod Drugs 0.000 claims description 4
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 4
239000011780 sodium chloride Substances 0.000 claims description 4
KZQSXALQTHVPDQ-UHFFFAOYSA-M sodium;butanedioate;hydron Chemical group [Na+].OC(=O)CCC([O-])=O KZQSXALQTHVPDQ-UHFFFAOYSA-M 0.000 claims description 4
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
NAQWICRLNQSPPW-UHFFFAOYSA-N 1,2,3,4-tetrachloronaphthalene Chemical group C1=CC=CC2=C(Cl)C(Cl)=C(Cl)C(Cl)=C21 NAQWICRLNQSPPW-UHFFFAOYSA-N 0.000 claims description 3
229920002498 Beta-glucan Polymers 0.000 claims description 3
GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims description 3
GOWLTLODGKPXMN-MEKRSRHXSA-N OM-174 Chemical compound O1[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1CO[C@H]1[C@H](NC(=O)C[C@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 GOWLTLODGKPXMN-MEKRSRHXSA-N 0.000 claims description 3
229940044665 STING agonist Drugs 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 3
108010017271 denileukin diftitox Proteins 0.000 claims description 3
239000002526 disodium citrate Substances 0.000 claims description 3
235000019262 disodium citrate Nutrition 0.000 claims description 3
CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical group [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 claims description 3
229940056913 eftilagimod alfa Drugs 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229940100027 ontak Drugs 0.000 claims description 3
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 3
239000001509 sodium citrate Substances 0.000 claims description 3
150000003890 succinate salts Chemical class 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
229940038773 trisodium citrate Drugs 0.000 claims description 3
241000272478 Aquila Species 0.000 claims description 2
108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 claims description 2
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
229940124597 therapeutic agent Drugs 0.000 claims description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
125000001142 dicarboxylic acid group Chemical group 0.000 claims 1
MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 claims 1
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 108
229940024606 amino acid Drugs 0.000 description 91
235000001014 amino acid Nutrition 0.000 description 85
ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical group [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 73
229940074404 sodium succinate Drugs 0.000 description 69
239000012648 POLY-ICLC Substances 0.000 description 60
229940115270 poly iclc Drugs 0.000 description 60
108700002563 poly ICLC Proteins 0.000 description 48
239000002904 solvent Substances 0.000 description 41
239000011347 resin Substances 0.000 description 30
229920005989 resin Polymers 0.000 description 30
210000004027 cell Anatomy 0.000 description 29
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 19
150000001875 compounds Chemical class 0.000 description 18
238000005859 coupling reaction Methods 0.000 description 18
235000018102 proteins Nutrition 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 17
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
239000000872 buffer Substances 0.000 description 16
230000035772 mutation Effects 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
208000009956 adenocarcinoma Diseases 0.000 description 15
239000002585 base Substances 0.000 description 15
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
238000003786 synthesis reaction Methods 0.000 description 14
150000007513 acids Chemical class 0.000 description 13
238000010511 deprotection reaction Methods 0.000 description 13
239000011550 stock solution Substances 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
230000008878 coupling Effects 0.000 description 12
238000010168 coupling process Methods 0.000 description 12
230000002209 hydrophobic effect Effects 0.000 description 12
230000009826 neoplastic cell growth Effects 0.000 description 11
201000009030 Carcinoma Diseases 0.000 description 10
206010039491 Sarcoma Diseases 0.000 description 10
201000001441 melanoma Diseases 0.000 description 10
206010041823 squamous cell carcinoma Diseases 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
238000007792 addition Methods 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
238000001556 precipitation Methods 0.000 description 9
238000012163 sequencing technique Methods 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 8
108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
210000001744 T-lymphocyte Anatomy 0.000 description 8
102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 8
230000027455 binding Effects 0.000 description 8
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
238000013461 design Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
230000028993 immune response Effects 0.000 description 8
210000000987 immune system Anatomy 0.000 description 8
241000282412 Homo Species 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
239000011877 solvent mixture Substances 0.000 description 7
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 6
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
206010038389 Renal cancer Diseases 0.000 description 6
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
210000004899 c-terminal region Anatomy 0.000 description 6
229940022399 cancer vaccine Drugs 0.000 description 6
150000001768 cations Chemical class 0.000 description 6
238000002156 mixing Methods 0.000 description 6
239000008188 pellet Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
239000013603 viral vector Substances 0.000 description 6
OXEDICXRSSILSN-GOTSBHOMSA-N (4s)-3-[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoyl]-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)COC(C)(C)C)N1[C@H](C(O)=O)COC1(C)C OXEDICXRSSILSN-GOTSBHOMSA-N 0.000 description 5
201000008808 Fibrosarcoma Diseases 0.000 description 5
208000008839 Kidney Neoplasms Diseases 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
238000009566 cancer vaccine Methods 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
235000015165 citric acid Nutrition 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
239000006184 cosolvent Substances 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
201000010982 kidney cancer Diseases 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
239000000463 material Substances 0.000 description 5
244000052769 pathogen Species 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000008163 sugars Chemical class 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
239000013598 vector Substances 0.000 description 5
FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 4
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
206010004146 Basal cell carcinoma Diseases 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
229920000858 Cyclodextrin Polymers 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
208000017604 Hodgkin disease Diseases 0.000 description 4
208000010747 Hodgkins lymphoma Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
206010060862 Prostate cancer Diseases 0.000 description 4
208000000236 Prostatic Neoplasms Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
230000005867 T cell response Effects 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000003511 endothelial effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
238000007481 next generation sequencing Methods 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
201000008968 osteosarcoma Diseases 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
238000000734 protein sequencing Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000011179 visual inspection Methods 0.000 description 4
SYGKUYKLHYQKPL-NRFANRHFSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-(3-methylpentan-3-yloxy)-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(CC)CC)C(O)=O)C3=CC=CC=C3C2=C1 SYGKUYKLHYQKPL-NRFANRHFSA-N 0.000 description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
206010069754 Acquired gene mutation Diseases 0.000 description 3
208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
108700028369 Alleles Proteins 0.000 description 3
201000003076 Angiosarcoma Diseases 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
208000001258 Hemangiosarcoma Diseases 0.000 description 3
241000701806 Human papillomavirus Species 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
108091054437 MHC class I family Proteins 0.000 description 3
108010021466 Mutant Proteins Proteins 0.000 description 3
102000008300 Mutant Proteins Human genes 0.000 description 3
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
206010029260 Neuroblastoma Diseases 0.000 description 3
208000010191 Osteitis Deformans Diseases 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
208000007452 Plasmacytoma Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
208000006265 Renal cell carcinoma Diseases 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
235000011054 acetic acid Nutrition 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
229910000147 aluminium phosphate Inorganic materials 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
235000003704 aspartic acid Nutrition 0.000 description 3
230000008901 benefit Effects 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
208000029742 colonic neoplasm Diseases 0.000 description 3
239000008139 complexing agent Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000001530 fumaric acid Substances 0.000 description 3
229940093915 gynecological organic acid Drugs 0.000 description 3
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
125000001165 hydrophobic group Chemical group 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000002198 insoluble material Substances 0.000 description 3
206010024627 liposarcoma Diseases 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
208000020816 lung neoplasm Diseases 0.000 description 3
239000001630 malic acid Substances 0.000 description 3
235000011090 malic acid Nutrition 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
208000007538 neurilemmoma Diseases 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
235000005985 organic acids Nutrition 0.000 description 3
229940023041 peptide vaccine Drugs 0.000 description 3
229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
239000011591 potassium Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
230000002265 prevention Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
230000037439 somatic mutation Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
230000008685 targeting Effects 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 2
REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 2
CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 2
BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 2
OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 2
QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 2
LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 2
DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
206010000830 Acute leukaemia Diseases 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
206010003571 Astrocytoma Diseases 0.000 description 2
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
206010006417 Bronchial carcinoma Diseases 0.000 description 2
201000000274 Carcinosarcoma Diseases 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
208000005243 Chondrosarcoma Diseases 0.000 description 2
201000009047 Chordoma Diseases 0.000 description 2
208000006332 Choriocarcinoma Diseases 0.000 description 2
208000009798 Craniopharyngioma Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
201000009051 Embryonal Carcinoma Diseases 0.000 description 2
206010014967 Ependymoma Diseases 0.000 description 2
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
208000036566 Erythroleukaemia Diseases 0.000 description 2
208000006168 Ewing Sarcoma Diseases 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
206010069755 K-ras gene mutation Diseases 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
208000003351 Melanosis Diseases 0.000 description 2
206010027406 Mesothelioma Diseases 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
241000714177 Murine leukemia virus Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
201000010133 Oligodendroglioma Diseases 0.000 description 2
208000027868 Paget disease Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
238000003559 RNA-seq method Methods 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
241000713311 Simian immunodeficiency virus Species 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
208000021712 Soft tissue sarcoma Diseases 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
208000017733 acquired polycythemia vera Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
208000024447 adrenal gland neoplasm Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000032683 aging Effects 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
239000003098 androgen Substances 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
208000003362 bronchogenic carcinoma Diseases 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
208000024207 chronic leukemia Diseases 0.000 description 2
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
208000002445 cystadenocarcinoma Diseases 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
239000000412 dendrimer Substances 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
229920000736 dendritic polymer Polymers 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
229940052303 ethers for general anesthesia Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012537 formulation buffer Substances 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
239000011521 glass Substances 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
208000025750 heavy chain disease Diseases 0.000 description 2
201000002222 hemangioblastoma Diseases 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
230000036737 immune function Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
229960005386 ipilimumab Drugs 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
230000021633 leukocyte mediated immunity Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
229910052744 lithium Inorganic materials 0.000 description 2
208000014018 liver neoplasm Diseases 0.000 description 2
208000012804 lymphangiosarcoma Diseases 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
239000011976 maleic acid Substances 0.000 description 2
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
208000027202 mammary Paget disease Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
206010027191 meningioma Diseases 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
239000000693 micelle Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
208000001611 myxosarcoma Diseases 0.000 description 2
239000002086 nanomaterial Substances 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000001139 pH measurement Methods 0.000 description 2
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
208000004019 papillary adenocarcinoma Diseases 0.000 description 2
201000010198 papillary carcinoma Diseases 0.000 description 2
229960000639 pazopanib Drugs 0.000 description 2
CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
210000004560 pineal gland Anatomy 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
208000037244 polycythemia vera Diseases 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000012088 reference solution Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
208000000587 small cell lung carcinoma Diseases 0.000 description 2
ZBTUYCUNQBRXOR-UHFFFAOYSA-L sodium succinate hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O ZBTUYCUNQBRXOR-UHFFFAOYSA-L 0.000 description 2
229940074453 sodium succinate hexahydrate Drugs 0.000 description 2
238000000527 sonication Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000008362 succinate buffer Substances 0.000 description 2
201000010965 sweat gland carcinoma Diseases 0.000 description 2
201000008753 synovium neoplasm Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
201000002510 thyroid cancer Diseases 0.000 description 2
238000013519 translation Methods 0.000 description 2
229950007217 tremelimumab Drugs 0.000 description 2
ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
239000012646 vaccine adjuvant Substances 0.000 description 2
229940124931 vaccine adjuvant Drugs 0.000 description 2
239000004034 viscosity adjusting agent Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 1
RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010000599 Acromegaly Diseases 0.000 description 1
206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
108020004513 Bacterial RNA Proteins 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
201000011057 Breast sarcoma Diseases 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
101100194816 Caenorhabditis elegans rig-3 gene Proteins 0.000 description 1
102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
241000282465 Canis Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
238000001353 Chip-sequencing Methods 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008642 Cholesteatoma Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
239000001263 FEMA 3042 Substances 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016935 Follicular thyroid cancer Diseases 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000021309 Germ cell tumor Diseases 0.000 description 1
241000713813 Gibbon ape leukemia virus Species 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
206010018404 Glucagonoma Diseases 0.000 description 1
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
108010075704 HLA-A Antigens Proteins 0.000 description 1
108010058607 HLA-B Antigens Proteins 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 description 1
101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
241000341655 Human papillomavirus type 16 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
206010073086 Iris melanoma Diseases 0.000 description 1
208000009164 Islet Cell Adenoma Diseases 0.000 description 1
208000017670 Juvenile Paget disease Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
208000030289 Lymphoproliferative disease Diseases 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000009018 Medullary thyroid cancer Diseases 0.000 description 1
206010027145 Melanocytic naevus Diseases 0.000 description 1
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
208000007256 Nevus Diseases 0.000 description 1
206010029488 Nodular melanoma Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010053869 POEMS syndrome Diseases 0.000 description 1
208000027067 Paget disease of bone Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033701 Papillary thyroid cancer Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010026552 Proteome Proteins 0.000 description 1
108090000944 RNA Helicases Proteins 0.000 description 1
102000004409 RNA Helicases Human genes 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
102100024324 Toll-like receptor 3 Human genes 0.000 description 1
102100039360 Toll-like receptor 4 Human genes 0.000 description 1
206010073104 Tubular breast carcinoma Diseases 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000005969 Uveal melanoma Diseases 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
206010047741 Vulval cancer Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 1
208000012018 Yolk sac tumor Diseases 0.000 description 1
AAELHWDCDSZXGG-UHFFFAOYSA-L [Na+].[Cl+].[Cl-].[Cl-] Chemical compound [Na+].[Cl+].[Cl-].[Cl-] AAELHWDCDSZXGG-UHFFFAOYSA-L 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
230000004913 activation Effects 0.000 description 1
208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
201000008395 adenosquamous carcinoma Diseases 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
229940086737 allyl sucrose Drugs 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000003373 basosquamous carcinoma Diseases 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
238000003766 bioinformatics method Methods 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
208000016738 bone Paget disease Diseases 0.000 description 1
206010006007 bone sarcoma Diseases 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
201000010983 breast ductal carcinoma Diseases 0.000 description 1
201000007476 breast mucinous carcinoma Diseases 0.000 description 1
201000000135 breast papillary carcinoma Diseases 0.000 description 1
229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
208000025188 carcinoma of pharynx Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229960002412 cediranib Drugs 0.000 description 1
229940047495 celebrex Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
208000012191 childhood neoplasm Diseases 0.000 description 1
VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
229960002023 chloroprocaine Drugs 0.000 description 1
208000006990 cholangiocarcinoma Diseases 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000562 conjugate Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000013058 crude material Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
201000010064 diabetes insipidus Diseases 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
208000001991 endodermal sinus tumor Diseases 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
238000003804 extraction from natural source Methods 0.000 description 1
201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
208000024519 eye neoplasm Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
230000004927 fusion Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
201000010175 gallbladder cancer Diseases 0.000 description 1
LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000012268 genome sequencing Methods 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000006359 hepatoblastoma Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
210000005007 innate immune system Anatomy 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000000244 kidney pelvis Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
229960000511 lactulose Drugs 0.000 description 1
PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
208000003849 large cell carcinoma Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
MHCFAGZWMAWTNR-UHFFFAOYSA-M lithium perchlorate Chemical compound [Li+].[O-]Cl(=O)(=O)=O MHCFAGZWMAWTNR-UHFFFAOYSA-M 0.000 description 1
229910001486 lithium perchlorate Inorganic materials 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000002350 malignant ciliary body melanoma Diseases 0.000 description 1
201000004593 malignant giant cell tumor Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
208000030163 medullary breast carcinoma Diseases 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000036438 mutation frequency Effects 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical group CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
210000000276 neural tube Anatomy 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
201000000032 nodular malignant melanoma Diseases 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
201000002575 ocular melanoma Diseases 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000009234 osteosclerotic myeloma Diseases 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
108010091742 peptide F Proteins 0.000 description 1
RJSZPKZQGIKVAU-UXBJKDEOSA-N peptide f Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C(C)C)C(C)C)C1=CC=CC=C1 RJSZPKZQGIKVAU-UXBJKDEOSA-N 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical group O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
208000031223 plasma cell leukemia Diseases 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920000233 poly(alkylene oxides) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
208000015768 polyposis Diseases 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
201000002709 prostate leiomyosarcoma Diseases 0.000 description 1
201000009474 prostate rhabdomyosarcoma Diseases 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000575 proteomic method Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000005185 salting out Methods 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
201000007321 sebaceous carcinoma Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
229960003310 sildenafil Drugs 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000037436 splice-site mutation Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
229950000244 sulfanilic acid Drugs 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
229960001796 sunitinib Drugs 0.000 description 1
208000030457 superficial spreading melanoma Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
229960000835 tadalafil Drugs 0.000 description 1
IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
229920002258 tannic acid Polymers 0.000 description 1
235000015523 tannic acid Nutrition 0.000 description 1
229940033123 tannic acid Drugs 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000440 toxicity profile Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000011222 transcriptome analysis Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
230000005945 translocation Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
238000004704 ultra performance liquid chromatography Methods 0.000 description 1
229910021642 ultra pure water Inorganic materials 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
208000037965 uterine sarcoma Diseases 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
229950008737 vadimezan Drugs 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
229960002381 vardenafil Drugs 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
208000008662 verrucous carcinoma Diseases 0.000 description 1
229960000834 vinyl ether Drugs 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
201000005102 vulva cancer Diseases 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000007482 whole exome sequencing Methods 0.000 description 1
238000012070 whole genome sequencing analysis Methods 0.000 description 1
229960001515 yellow fever vaccine Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Mycology (AREA)
Oncology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

TW108113861A 2018-04-19 2019-04-19 肽調配物及其用途 TW202011982A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862660027P	2018-04-19	2018-04-19
US62/660,027		2018-04-19

Publications (1)

Publication Number	Publication Date
TW202011982A true TW202011982A (zh)	2020-04-01

Family

ID=68239935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW108113861A TW202011982A (zh)	2018-04-19	2019-04-19	肽調配物及其用途

Country Status (3)

Country	Link
AR (1)	AR115346A1 (fr)
TW (1)	TW202011982A (fr)
WO (1)	WO2019204663A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL269830B2 (en)	2017-04-04	2024-01-01	Avidea Tech Inc	Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3234193B1 (fr) *	2014-12-19	2020-07-15	Massachusetts Institute of Technology	Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
TW202241500A (zh) *	2015-06-09	2022-11-01	美商博德研究所有限公司	用於贅瘤疫苗之調配物及其製備方法
IL269830B2 (en) *	2017-04-04	2024-01-01	Avidea Tech Inc	Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response

2019
- 2019-04-18 WO PCT/US2019/028204 patent/WO2019204663A1/fr not_active Ceased
- 2019-04-19 TW TW108113861A patent/TW202011982A/zh unknown
- 2019-04-22 AR ARP190101049A patent/AR115346A1/es unknown

Also Published As

Publication number	Publication date
WO2019204663A1 (fr)	2019-10-24
AR115346A1 (es)	2020-12-23

Publication	Publication Date	Title
JP7535489B2 (ja)	2024-08-16	治療用抗癌ネオエピトープワクチン
AU2020230295B2 (en)	2024-03-07	Formulations for neoplasia vaccines
JP7732024B2 (ja)	2025-09-01	異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
TWI750122B (zh)	2021-12-21	用於贅瘤疫苗之調配物及其製備方法
ES3036912T3 (en)	2025-09-25	Neoantigens and methods of their use
JP6560261B2 (ja)	2019-08-14	数種の血液腫瘍、特に慢性リンパ性白血病（ｃｌｌ）に対する新規免疫療法
TW202513579A (zh)	2025-04-01	新抗原及其用途
ES2970223T3 (es)	2024-05-27	Péptidos
JP2023523664A (ja)	2023-06-07	改善されたネオエピトープワクチン及びがんを治療するための方法
JP2024001045A (ja)	2024-01-09	Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
CN106163540A (zh)	2016-11-23	用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合
JP2023522512A (ja)	2023-05-31	共通のネオエピトープワクチンのための改善された組成物及び方法
TW202011982A (zh)	2020-04-01	肽調配物及其用途
JP2020014460A (ja)	2020-01-30	数種の血液腫瘍、特に慢性リンパ性白血病（ｃｌｌ）に対する新規免疫療法
JP2023030082A (ja)	2023-03-07	Ａｍｌおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US11191828B2 (en)	2021-12-07	MHC class I associated hepatitis B peptides
RU2813924C2 (ru)	2024-02-19	Неоантигены и их применение
HK40086688A (zh)	2023-09-01	新抗原及其使用方法
WO2021129898A2 (fr)	2021-07-01	Polypeptides qui comprennent des mutants du vegf-a humain avec ré-arrangements de ponts disulfure et compositions qui les contiennent
HK1228249A1 (en)	2017-11-03	Formulations for neoplasia vaccines
HK1228249B (en)	2022-10-28	Formulations for neoplasia vaccines